WVE-120101

DRUG2 trials

Sponsors

Wave Life Sciences Ltd.

Conditions

Huntington DiseaseHuntington's Disease

Phase 1

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

TerminatedNCT03225833

Wave Life Sciences Ltd.Huntington's Disease

Start: 2017-07-17End: 2021-05-11Updated: 2022-02-10

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

TerminatedNCT04617847

Wave Life Sciences Ltd.Huntington Disease

Start: 2020-04-13End: 2021-05-03Updated: 2022-02-09

Related Papers

Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT

Molecular Therapy — Nucleic Acids2024-06-1111 citations

An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons.

2022-11-1050 citations

Huntington’s Disease Clinical Trials Corner: August 2018

Journal of Huntington s Disease2018-06-0131 citations

Huntington’s Disease Clinical Trials Corner: February 2018

2018-01-0144 citations